Design and Synthesis of Tesirine, a Clinical Antibody–Drug Conjugate Pyrrolobenzodiazepine Dimer Payload

• Published in: ACS medicinal chemistry letters Vol. 7; no. 11; pp. 983 - 987
• Main Authors: Tiberghien, Arnaud C, Levy, Jean-Noel, Masterson, Luke A, Patel, Neki V, Adams, Lauren R, Corbett, Simon, Williams, David G, Hartley, John A, Howard, Philip W
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 10.11.2016
• Subjects: Letter; antibody−drug conjugates; SG3249; talirine; Tesirine; Rova-T
• ISSN: 1948-5875; 1948-5875
• DOI: 10.1021/acsmedchemlett.6b00062

Pyrrolobenzodiazepine dimers are an emerging class of warhead in the field of antibody–drug conjugates (ADCs). Tesirine (SG3249) was designed to combine potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. One of the reactive imines was capped with a cathepsin B-cleavable valine-alanine linker. A robust synthetic route was developed to allow the production of tesirine on clinical scale, employing a flexible, convergent strategy. Tesirine was evaluated in vitro both in stochastic and engineered ADC constructs and was confirmed as a potent and versatile payload. The conjugation of tesirine to anti-DLL3 rovalpituzumab has resulted in rovalpituzumab-tesirine (Rova-T), currently under evaluation for the treatment of small cell lung cancer.